MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction
暂无分享,去创建一个
[1] Xian-fu Sun,et al. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer , 2015, PloS one.
[2] H. Wildiers,et al. Circulating MicroRNAs as Easy-to-Measure Aging Biomarkers in Older Breast Cancer Patients: Correlation with Chronological Age but Not with Fitness/Frailty Status , 2014, PloS one.
[3] Carrie L. Griffiths,et al. Triple Negative Breast Cancer: A Brief Review of its Characteristics and Treatment Options , 2012, Journal of pharmacy practice.
[4] H. Brauch,et al. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. , 2013, European journal of cancer.
[5] Vicki Livingstone,et al. Interventions for relieving the pain and discomfort of screening mammography. , 2008, The Cochrane database of systematic reviews.
[6] E. Kroh,et al. Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies , 2011, Cancer Prevention Research.
[7] A. Harris,et al. Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.
[8] M. Yigit,et al. The role of microRNA in resistance to breast cancer therapy , 2014, Wiley interdisciplinary reviews. RNA.
[9] Jian-xin Gao,et al. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. , 2013, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[10] Yingjian Chen,et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer , 2012, Journal of Cancer Research and Clinical Oncology.
[11] Use of miRNAs in biofluids as biomarkers in dietary and lifestyle intervention studies , 2015, Genes & Nutrition.
[12] Jessica A. Weber,et al. The microRNA spectrum in 12 body fluids. , 2010, Clinical chemistry.
[13] Li Guo,et al. Next-Generation Sequencing of MicroRNAs for Breast Cancer Detection , 2011, Journal of biomedicine & biotechnology.
[14] Chun-Wen Cheng,et al. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer , 2012, Breast Cancer Research and Treatment.
[15] Hongjiang Wang,et al. Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer , 2012, PloS one.
[16] J. Xiang,et al. HER2-directed therapy: current treatment options for HER2-positive breast cancer , 2015, Breast Cancer.
[17] H. Gilbert Welch,et al. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence , 2013 .
[18] Zheng-sheng Wu,et al. Prognostic significance of let-7b expression in breast cancer and correlation to its target gene of BSG expression , 2013, Medical Oncology.
[19] D. Weigel,et al. Transcriptional Control of Gene Expression by MicroRNAs , 2010, Cell.
[20] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[21] Ligang Wu,et al. MicroRNAs direct rapid deadenylation of mRNA. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[22] S. Volinia,et al. Comparison of MicroRNA Deep Sequencing of Matched Formalin-Fixed Paraffin-Embedded and Fresh Frozen Cancer Tissues , 2013, PloS one.
[23] P. Seeburg,et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases , 2006, Nature Structural &Molecular Biology.
[24] D. Duelli,et al. Supplemental Materials and Methods: Linker Ligation , 2022 .
[25] Ling Qiu,et al. MicroRNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells. , 2015, Oncology reports.
[26] G. Yousef,et al. Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. , 2014, Clinical chemistry.
[27] Zebo Huang,et al. An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer , 2014, Journal of experimental & clinical cancer research : CR.
[28] L. Pusztai,et al. Multigene prognostic tests in breast cancer: past, present, future , 2015, Breast Cancer Research.
[29] Maria Peña-Chilet,et al. MicroRNA profile in very young women with breast cancer , 2014, BMC Cancer.
[30] J. Russo,et al. Techniques and Methodological Approaches in Breast Cancer Research , 2014, Springer New York.
[31] E. Mardis,et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay , 2015, BMC Medical Genomics.
[32] V. Ambros,et al. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.
[33] Xiang-Sun Zhang,et al. Breast tumor subgroups reveal diverse clinical prognostic power , 2014, Scientific Reports.
[34] Yang Luo,et al. Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel , 2014, PloS one.
[35] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[36] M. Matboli,et al. Breast tissue-based microRNA panel highlights microRNA-23a and selected target genes as putative biomarkers for breast cancer. , 2015, Translational research : the journal of laboratory and clinical medicine.
[37] Qiong Shao,et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.
[38] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[39] G. Calin,et al. Identification of circulating MicroRNA signatures for breast cancer detection , 2014 .
[40] Ava Kwong,et al. Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection , 2013, PloS one.
[41] C. Sotiriou,et al. Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer , 2011, PloS one.
[42] Hua Zhao,et al. A Pilot Study of Circulating miRNAs as Potential Biomarkers of Early Stage Breast Cancer , 2010, PloS one.
[43] N. Kondo,et al. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. , 2012, Japanese journal of clinical oncology.
[44] M. Caligiuri,et al. miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts , 2010, Cell.
[45] Yu Sun,et al. Serum MicroRNA-155 as a Potential Biomarker to Track Disease in Breast Cancer , 2012, PloS one.
[46] Dieter Jocham,et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. , 2010, Urologic oncology.
[47] Kai Fu,et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. , 2012, Cancer cell.
[48] L. Pfeffer,et al. MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity , 2015, Oncogene.
[49] Olli Kallioniemi,et al. High‐throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth , 2014, Molecular oncology.
[50] Graham Ball,et al. Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer , 2014, PloS one.
[51] X. Chen,et al. Secreted microRNAs: a new form of intercellular communication. , 2012, Trends in cell biology.
[52] Yulei N. Wang,et al. Plasma miRNA as Biomarkers for Assessment of Total-Body Radiation Exposure Dosimetry , 2011, PloS one.
[53] L. Paz-Ares,et al. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. , 2013, Carcinogenesis.
[54] Muneesh Tewari,et al. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). , 2010, Methods.
[55] Daniel B. Martin,et al. Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.
[56] A. Arance,et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.
[57] Barbara Burwinkel,et al. Extracellular miRNAs: the mystery of their origin and function. , 2012, Trends in biochemical sciences.
[58] Nicola J. Armstrong,et al. Haemolysis during Sample Preparation Alters microRNA Content of Plasma , 2011, PloS one.
[59] George A Calin,et al. A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients , 2014, Clinical Cancer Research.
[60] Jennifer M. Carr,et al. Multi-Platform Analysis of MicroRNA Expression Measurements in RNA from Fresh Frozen and FFPE Tissues , 2013, PloS one.
[61] Songjie Shen,et al. A Prognostic Model of Triple-Negative Breast Cancer Based on miR-27b-3p and Node Status , 2014, PloS one.
[62] Eduardo Andrés-León,et al. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. , 2015, Clinical chemistry.
[63] Da-cheng Han,et al. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer , 2014, Molecular Biology Reports.
[64] Michael J. Kerin,et al. Effects of Age on the Detection and Management of Breast Cancer , 2015, Cancers.
[65] Jian-yong Li,et al. Downregulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia , 2012, Cancer science.
[66] Rebecca A Hubbard,et al. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. , 2013, JAMA internal medicine.
[67] P. Narula. MAMMOGRAPHIC DENSITY AND THE RISK AND DETECTION OF BREAST CANCER , 2016 .
[68] J. García-Saenz,et al. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] Lianhong Li,et al. Regulation of breast cancer tumorigenesis and metastasis by miRNAs , 2012, Expert review of proteomics.
[70] Jiyon Lee,et al. The relationship of mammographic density and age: implications for breast cancer screening. , 2012, AJR. American journal of roentgenology.
[71] M. Kay,et al. How do miRNAs mediate translational repression? , 2010, Silence.
[72] Gozoh Tsujimoto,et al. Intra-Platform Repeatability and Inter-Platform Comparability of MicroRNA Microarray Technology , 2009, PloS one.
[73] E. Kroh,et al. Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels , 2013, PloS one.
[74] H. Iwase,et al. [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[75] S. Tishkoff,et al. Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers , 2014, BMC Medical Genomics.
[76] R. Rosenfeld. Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[77] Ying Zhu,et al. MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers , 2014, BMC Cancer.
[78] E. Ng,et al. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer , 2015, British Journal of Cancer.
[79] X Wang,et al. MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin , 2014, Oncogene.
[80] Axel Benner,et al. Circulating microRNAs in plasma as early detection markers for breast cancer , 2013, International journal of cancer.
[81] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[82] I. Pogribny,et al. MicroRNA-mediated drug resistance in breast cancer , 2011, Clinical Epigenetics.
[83] M. Martínez-Larrad,et al. Serum Circulating microRNA Profiling for Identification of Potential Type 2 Diabetes and Obesity Biomarkers , 2013, PloS one.
[84] H. Binder,et al. Novel circulating microRNA signature as a potential non‐invasive multi‐marker test in ER‐positive early‐stage breast cancer: A case control study , 2014, Molecular oncology.
[85] R. Kittles,et al. Evaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human Cancers , 2016, Journal of Cancer.
[86] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] Seho Park,et al. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers , 2013, Breast Cancer Research and Treatment.
[88] Christopher A. Loffredo,et al. MicroRNA-9 as Potential Biomarker for Breast Cancer Local Recurrence and Tumor Estrogen Receptor Status , 2012, PloS one.
[89] M. L. Hastings,et al. Selective Release of MicroRNA Species from Normal and Malignant Mammary Epithelial Cells , 2010, PloS one.
[90] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[91] H. Braselmann,et al. Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells , 2012, Radiation oncology.
[92] Jingjing Liu,et al. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer , 2016, Cell Death and Disease.
[93] T. Stopka,et al. Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum , 2014, BMC Cancer.
[94] Evelyn Wenkel,et al. Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection , 2012, PloS one.
[95] J. Votaw,et al. MicroRNA-302 Replacement Therapy Sensitizes Breast Cancer Cells to Ionizing Radiation , 2012, Pharmaceutical Research.
[96] Ignace Vergote,et al. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management , 2015, Breast Cancer Research.
[97] Cristina Rodríguez-Padilla,et al. Serum Circulating microRNA Profiling for Identification of Potential Breast Cancer Biomarkers , 2013, Disease markers.
[98] S. Xie,et al. Higher expression of circulating miR-182 as a novel biomarker for breast cancer , 2013, Oncology letters.
[99] A. Hata,et al. Dysregulation of microRNA biogenesis machinery in cancer , 2016, Critical reviews in biochemistry and molecular biology.
[100] C. Morrison,et al. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers , 2014, Oncotarget.
[101] R. Bast,et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients , 2012, Cancer.
[102] Terry L. Smith,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] Leonard D. Goldstein,et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.
[104] Wei Zhang,et al. Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer , 2013, Medical Oncology.
[105] V. Tarasov,et al. Differential Regulation of microRNAs by p53 Revealed by Massively Parallel Sequencing: miR-34a is a p53 Target That Induces Apoptosis and G1-arrest , 2007, Cell cycle.
[106] Eun Sook Lee,et al. Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast , 2011, Journal of breast cancer.
[107] Li Guo,et al. The Fate of miRNA* Strand through Evolutionary Analysis: Implication for Degradation As Merely Carrier Strand or Potential Regulatory Molecule? , 2010, PloS one.
[108] Deyao Zhao,et al. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer , 2015, Breast Cancer Research and Treatment.
[109] Jin Gao,et al. Prognostic value of miR-106b expression in breast cancer patients. , 2015, The Journal of surgical research.
[110] Steven R. Head,et al. Next-generation sequencing , 2010, Nature Reviews Drug Discovery.
[111] S. Du,et al. MiR-200 c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN 1 , 2014 .
[112] Yaping Tian,et al. A novel panel of microRNAs provides a sensitive and specific tool for the diagnosis of breast cancer. , 2014, Molecular medicine reports.
[113] T. Blondal,et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. , 2013, Methods.
[114] Weiying Zhou,et al. UC Office of the President Recent Work Title De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer , 2012 .
[115] Annuska M Glas,et al. Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer , 2010, Biomarker insights.
[116] Hua Zhao,et al. Genetic variants in microRNAs and breast cancer risk in African American and European American women , 2013, Breast Cancer Research and Treatment.
[117] Yibin Kang,et al. MicroRNA-711 is a prognostic factor for poor overall survival and has an oncogenic role in breast cancer. , 2016, Oncology letters.
[118] A. Hutcheon,et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.
[119] Bushra Riaz,et al. BREAST TUMOR , 2018, The Professional Medical Journal.
[120] K. Ang,et al. miR-205 acts as a tumor radiosensitizer by targeting ZEB1 and Ubc13 , 2014, Nature Communications.
[121] Chang Gong,et al. Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer* , 2011, The Journal of Biological Chemistry.
[122] C. Shin,et al. MicroRNA-directed cleavage of targets: mechanism and experimental approaches , 2014, BMB reports.
[123] Lei Ma,et al. Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. , 2014, International journal of clinical and experimental pathology.
[124] Jack A. Taylor,et al. Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort , 2013, Breast Cancer Research.
[125] Y. Tomari,et al. The N domain of Argonaute drives duplex unwinding during RISC assembly , 2012, Nature Structural &Molecular Biology.
[126] F. Yu,et al. Reduced Let-7a Is Associated with Chemoresistance in Primary Breast Cancer , 2015, PloS one.
[127] Sota Asaga,et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. , 2011, Clinical chemistry.
[128] Yong-qiang Ren,et al. MiR-27a Modulates Radiosensitivity of Triple-Negative Breast Cancer (TNBC) Cells by Targeting CDC27 , 2015, Medical science monitor : international medical journal of experimental and clinical research.
[129] David J. Galas,et al. Comparing the MicroRNA Spectrum between Serum and Plasma , 2012, PloS one.
[130] F. Yu,et al. Plasma miR-221 as a Predictive Biomarker for Chemoresistance in Breast Cancer Patients who Previously Received Neoadjuvant Chemotherapy , 2011, Oncology Research and Treatment.
[131] Ulrich Bodenhofer,et al. Hsa-miR-375 is a predictor of local control in early stage breast cancer , 2016, Clinical Epigenetics.
[132] D. Marsh,et al. Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs , 2016, PloS one.
[133] C. Croce,et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[134] Lijuan Guo,et al. Decreased serum miR-181a is a potential new tool for breast cancer screening. , 2012, International journal of molecular medicine.
[135] Sanghamitra Bandyopadhyay,et al. MicroRNA signatures highlight new breast cancer subtypes. , 2015, Gene.
[136] C. Fox,et al. Breast-cancer screening. , 1979, Lancet.
[137] F. Yu,et al. MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient Survival , 2012, PloS one.
[138] F. Lumachi,et al. Current medical treatment of estrogen receptor-positive breast cancer. , 2015, World journal of biological chemistry.
[139] D. Pisano,et al. Mechanistic principles of chromatin remodeling guided by siRNAs and miRNAs , 2008, Cell cycle.
[140] Carlos Caldas,et al. Biological and prognostic associations of miR‐205 and let‐7b in breast cancer revealed by in situ hybridization analysis of micro‐RNA expression in arrays of archival tumour tissue , 2012, The Journal of pathology.
[141] “Monoallelic germline methylation and sequence variant in the promoter of the RB1 gene: a possible constitutive epimutation in hereditary retinoblastoma” , 2016, Clinical Epigenetics.
[142] A. Chung,et al. MicroRNA‐224 is up‐regulated in hepatocellular carcinoma through epigenetic mechanisms , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[143] J. Vandesompele,et al. Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo , 2010, Cell Death and Differentiation.
[144] Wei Li,et al. MicroRNA detection by microarray , 2009, Analytical and bioanalytical chemistry.
[145] C. Shin,et al. Slicer-independent mechanism drives small-RNA strand separation during human RISC assembly , 2015, Nucleic acids research.
[146] N. Bertos,et al. Breast cancer - one term, many entities? , 2011, The Journal of clinical investigation.
[147] D. Wilkinson. Gene Expression Patterns , 2002, Brain Research.
[148] J. Lieberman,et al. let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells , 2007, Cell.
[149] Michael J Kerin,et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. , 2010, The oncologist.
[150] X. Chen,et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.
[151] N. Kosaka,et al. microRNA as a new immune-regulatory agent in breast milk , 2010, Silence.
[152] S. Du,et al. MiR‐200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1 , 2015, International journal of cancer.
[153] C. Croce,et al. MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.
[154] N. Park,et al. Salivary microRNA: Discovery, Characterization, and Clinical Utility for Oral Cancer Detection , 2009, Clinical Cancer Research.
[155] U. Lehmann,et al. Epigenetic inactivation of microRNA gene hsa‐mir‐9‐1 in human breast cancer , 2008, The Journal of pathology.